Eton Pharmaceuticals (ETON) announced that it has acquired the U.S. rights to Amglidia for the treatment of neonatal diabetes mellitus from AMMTeK. AMMTeK has conducted a post-approval study tracking five years of real-world safety and efficacy in European patients, which will be used to support Eton’s NDA submission. Eton plans to hold a meeting with the FDA in the first quarter of 2025 and anticipates submitting an NDA for the product in 2026.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ETON:
- Eton Pharmaceuticals Reports Strong Q3 2024 Results
- Eton Pharmaceuticals reports Q3 EPS 2c, consensus (1c)
- ETON Earnings this Week: How Will it Perform?
- Eton Pharmaceuticals awarded second patent for ET-400
- Eton Pharmaceuticals price target raised to $15 from $10 at Craig-Hallum
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
